BACHADON BO'YNI SARATONI: DUNYO TAJRIBASI VA ZAMONAVIY TERAPIYA
Keywords:
bachadon bo'yni saratoni, inson papilloma virusi, skrining, immun terapiya, maqsadli davolash, vaksinatsiya, onkologiya, radiatsion terapiya, kimyoviy terapiya.Abstract
Ushbu maqolada bachadon bo'yni saratonining epidemiologik xususiyatlari, etiologik omillari, diagnostika usullari va zamonaviy davolash strategiyalari tahlil qilindi. Bachadon bo'yni saratoni ayollar o'rtasida eng ko'p uchraydigan xavfli o'simtalardan biri hisoblanadi va asosan inson papilloma virusi bilan bog'liqligi aniqlandi. Maqolada bachadon bo'yni saratonining oldini olish, skrining dasturlari, xirurgik muolaja, nurlanish terapiyasi va kimyoviy terapiya usullari keng ko'lamda o'rganildi. Dunyo mamlakatlarida qo'llanilayotgan ilg'or terapevtik yondashuvlar, immun terapiya va maqsadli davolash usullarining samaradorligi ko'rib chiqildi. Zamonaviy tibbiyotda bachadon bo'yni saratoniga qarshi kurashda kompleks yondashuv, erta diagnostika va vaksinatsiya dasturlarining ahamiyati yoritildi.
References
1. Cohen P.A., Jhingran A., Oaknin A., Denny L. Cervical cancer: Global health perspective. The Lancet, 2019, 393 (10167), 169-182 betlar.
2. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2018, 68 (6), 394-424 betlar.
3. Arbyn M., Weiderpass E., Bruni L., de Sanjosé S., Saraiya M., Ferlay J., Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 2020, 8 (2), e191-e203 betlar.
4. Tewari K.S., Sill M.W., Penson R.T., Huang H., Ramondetta L.M., Landrum L.M., Oaknin A., Reid T.J., Leitao M.M., Michael H.E. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial. The Lancet, 2017, 390 (10103), 1654-1663 betlar.
5. Chung H.C., Ros W., Delord J.P., Perets R., Italiano A., Shapira-Frommer R., Manzuk L., Piha-Paul S.A., Xu L., Zeigenfuss S., Pruitt S.K., Lewin J., Ott P.A. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 2019, 37 (17), 1470-1478 betlar.
6. Small W., Bacon M.A., Bajaj A., Chuang L.T., Fisher B.J., Harkenrider M.M., Jhingran A., Kitchener H.C., Mileshkin L.R., Viswanathan A.N., Gaffney D.K. Cervical cancer: A global health crisis. Cancer, 2017, 123 (13), 2404-2412 betlar.
7. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology, 1999, 189 (1), 12-19 betlar.
8. Hu Z., Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Medicine, 2018, 7 (10), 5217-5236 betlar.
9. Monk B.J., Sill M.W., McMeekin D.S., Cohn D.E., Ramondetta L.M., Boardman C.H., Benda J., Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 2009, 27 (28), 4649-4655 betlar.
10. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. The Lancet, 2007, 370 (9590), 890-907 betlar.
11. Gaffney D.K., Erickson-Wittmann B.A., Jhingran A., Mayr N.A., Puthawala A.A., Moore D., Eifel P.J. ACR Appropriateness Criteria® on advanced cervical cancer expert panel on radiation oncology-gynecology. International Journal of Radiation Oncology, Biology, Physics, 2011, 81 (3), 609-614 betlar.
12. Lei J., Ploner A., Elfström K.M., Wang J., Roth A., Fang F., Sundström K., Dillner J., Sparén P. HPV vaccination and the risk of invasive cervical cancer. New England Journal of Medicine, 2020, 383 (14), 1340-1348 betlar.
